Cancer vaccine ALECSAT

Drug Profile

Cancer vaccine ALECSAT

Alternative Names: ALECSAT; Cytotoxic lymphocyte-based cancer vaccine - CytoVac

Latest Information Update: 17 Jun 2016

Price : $50

At a glance

  • Originator CytoVac
  • Class Cancer vaccines; Cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Pancreatic cancer; Prostate cancer

Most Recent Events

  • 14 Apr 2016 Phase-II development for Glioblastoma is ongoing in Denmark
  • 01 Mar 2016 Phase-II clinical trials in Glioblastoma (First-line therapy, Adjunctive treatment) in Sweden (IV) (NCT02799238)
  • 16 Jun 2015 CytoVac terminates phase II trial in Gliobastoma (Second-line therapy or greater, Recurrent disease) in Denmark (IV) (NCT02060955)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top